Anebulo Pharmaceuticals (ANEB) Research & Development (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Research & Development of $1.2 million for Q4 2025, down 4.57% year-over-year from $1.2 million in Q4 2024, and up 43.8% quarter-over-quarter from $809991.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Research & Development (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Research & Development for 6 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 4.57% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $3.7 million (changed 0.32% YoY), while the FY2025 annual figure was $4.3 million, up 21.16% from the prior year.
- Research & Development rose to $1.2 million in Q4 2025 per ANEB's latest filing, from $809991.0 in the prior quarter.
- Across five years, Research & Development topped out at $1.9 million in Q4 2022 and bottomed at $212936.0 in Q4 2021.
- Historically, Research & Development has averaged $1.0 million across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2021 — Research & Development jumped 3425.08% — and 2024, when it sank 67.0%.
- Anebulo Pharmaceuticals' Research & Development stood at $212936.0 in 2021, then surged by 778.16% to $1.9 million in 2022, then sank by 43.17% to $1.1 million in 2023, then advanced by 14.86% to $1.2 million in 2024, then retreated by 4.57% to $1.2 million in 2025.
- Business Quant data shows ANEB's Research & Development at $1.2 million in Q4 2025, $809991.0 in Q3 2025, and $1.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 809,991.00 |
| Jun 30, 2025 | 1.13 Mn |
| Mar 31, 2025 | 638,324.00 |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 467,706.00 |
| Mar 31, 2024 | 748,339.00 |
| Dec 31, 2023 | 1.06 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 915,363.00 |
| Dec 31, 2021 | 212,936.00 |
| Sep 30, 2021 | 715,098.00 |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 273,038.00 |